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Wilson disease is an autosomal disorder of copper transport caused by mutations in the ATP7B gene encoding a copper-transporting P-
type ATPase. The Long Evans Cinnamon (LEC) rat is an established animal model for Wilson disease. We have used structural homology
modelling of the N-terminal copper-binding region of the rat atp7b protein (rCBD) to reveal the presence of a domain, the fourth domain
(rD4), which was previously thought to be missing from rCBD. Although the CXXC motif is absent from rD4, the overall fold is preserved.
Using a wide range of techniques, rCBD is shown to undergo metal-induced secondary and tertiary structural changes similar to WCBD.
Competition 65Zn(II)-blot experiments with rCBD demonstrate a binding cooperativity unique to Cu(I). Far-UV circular dichroism (CD)
spectra suggest significant secondary structural transformation occurring when 2–3 molar equivalents of Cu(I) is added. Near-UV CD
spectra, which indicate tertiary structural transformations, show a proportional decrease in rCBD disulfide bonds upon the incremental
addition of Cu(I), and a maximum 5:1 Cu(I) to protein ratio. The similarity of these results to those obtained for the Wilson disease N-
terminal copper-binding region (WCBD), which has six copper-binding domains, suggests that the metal-dependent conformational changes
observed in both proteins may be largely determined by the protein–protein interactions taking place between the heavy metal-associated
(HMA) domains, and remain largely unaffected by the absence of one of the six CXXC copper-binding sites.
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Copper is an essential trace element necessary for the
proper functioning of many biological processes [1]. How-
ever, an excess or deficiency of copper in the body can lead
to a diseased state, thus necessitating careful regulation,
transport and storage of this metal [2]. Wilson disease is an
autosomal recessive disorder in which copper homeostasis is
severely affected and is characterized by the inability of
hepatocytes to incorporate copper into ceruloplasmin or to
effectively efflux copper from the liver [3]. These features
of Wilson disease are caused by mutations in ATP7B, a gene
encoding a transmembrane P-type ATPase (ATP7B) found
in the liver [4,5]. Menkes disease, a disorder of copper
absorption, is caused by mutations in ATP7A, a gene
encoding a P-type ATPase (ATP7A) highly similar to
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8]. Although these two diseases have near-opposite mani-
festations, the proteins involved have a high amino acid
sequence similarity to each other, and shown to have related
functions [9]. In Wilson disease, dysfunctional ATP7B
compromises biliary copper clearance, causing copper to
accumulate in the liver. Eventually, an overload of metal
leads to hepatic damage and the release of non-ceruloplas-
min bound copper, which ultimately accumulates in periph-
eral organs such as the brain, cornea and kidney [2].
Many biochemical similarities of Wilson disease have
been shown to exist in the Long Evans Cinnamon (LEC)1
rat [10,11]. The rat orthologue (atp7b) of ATP7B shows an
amino acid sequence that is 80% similar to its human
counterpart [10]. Furthermore, elevated serum copper con-
centrations and decreased amounts of ceruloplasmin estab-
lish the LEC rat as a suitable model for the study of Wilson
disease. The disease causing mutation is a deletion of 900
bp in the 3V terminus of atp7b gene; the gene is otherwise
identical to the wild-type rat gene, even in the region
encoding the N-terminus.
Over recent years, the N-termini of ATP7B and ATP7A
have received considerable attention, with many groups
hypothesizing that the function of this domain is vital for
copper transport as well as a key component of translocation
processes [12–15]. It is useful to compare characteristics of
atp7b, ATP7B, and ATP7A because of their close similar-
ities, yet having a difference involving the fourth domain of
their N-terminal copper-binding region. Within this extend-
ed family of ATPases, studies on the N-terminal copper-
binding region have focused on metal binding properties
and stoichiometry [16–18], copper-binding states to heavy
metal-associated (HMA) domains [19–22], cooperativity
[17,23], and mutational studies [12–14,24,25]. Despite this
extensive literature, work on comparative metal-induced
secondary and tertiary structural changes of the N-terminus
of these transporters is still incomplete.
Here we have combined a wide range of techniques to
probe the structure of the rat copper-transporting ATPase N-
terminal copper-binding region (rCBD) and to compare it to
the Wilson disease N-terminal copper-binding region
(WCBD). We use homology modelling to reveal the pres-
ence of a domain in rCBD, which was previously thought to
be absent from atp7b [10]. We show that this domain, the
fourth domain (rD4) of rCBD, has retained the typical fold
associated with HMA domains, even though it is missing
the CXXC (where X is any amino acid) Cu(I)-binding site.
We establish that rCBD and WCBD both contain six
domains, but unlike the six HMA domains found in WCBD,
only five of the domains in rCBD are HMA domains
containing the amino acid sequence CXXC. Our 65Zn(II)-
competition blotting and circular dichroism (CD) spectro-
scopic techniques reveal extensive similarities between the
metal-binding properties and metal-induced conformation
changes observed in rCBD and WCBD. We propose that the
conformational changes observed in the N-terminal copper-binding region are triggered initially by cooperative metal
binding to the domains, and then driven to completion by
favourable protein–protein contacts established among
some of the domains, and depend to a lesser extent on
metal binding.2. Materials and methods
2.1. Construction of atp7b copper-binding region cDNA
The cDNA fragment was generated by the polymerase
chain reaction (PCR) directly from a clonal phage lysate
(clone 7; [10]), containing the entire atp7b coding region
cDNA. PCR was carried out in a 50-Al volume using 1 unit
of pfu polymerase (Stratagene), 2 mM each of dATP, dCTP,
dGTP, and dTTP, 1.5 mM magnesium chloride, 50 ng of
each oligonucleotide primer and template cDNA in the
buffer supplied by the manufacturer. The reaction conditions
were 5 min at 95 jC for initial denaturation of template
cDNA followed by 20 cycles of 30 s 95 jC denaturation, 30
s 58 jC annealing, and 3 min 72 jC extension. The primers
used were as follows 5V-ACTGGGATCCATGCCTGAA-
CAGGAGAGAAAG-3V and 5V-ACTGGTCGACT-
CACTGTTTTATTTCCGTCTTGTG-3V. These primers
incorporate a 5V BamHI, and a 3V SalI restriction endonu-
clease site to enable cloning of the amplified cDNA frag-
ment. Following PCR amplification, the cDNA fragment
was purified by agarose gel electrophoresis, and recovered
from the excised gel slice using a QiaQuick Gel purification
kit (Qiagen) according to the manufacturer’s protocol. The
purified cDNA fragment was double-digested with BamHI
and SalI restriction endonucleases (New England Biolabs)
then subjected to a further round of gel purification as
described above. This cDNA fragment was ligated into
pUC19 vector (Pharmacia) double-digested with BamHI
and SalI restriction endonucleases (New England Biolabs)
and gel-purified as described above. Ligations were carried
out at 4 jC overnight using T4 DNA ligase (New England
Biolabs) in buffer supplied by the manufacturer. Ligated
DNA was transformed into XL-1Blue E. coli (Stratagene)
by electroporation (BioRad). Plasmid DNA was prepared
from carbenicillin selected E. coli clones using Qiagen
Miniprep Spin columns according to the manufacturer’s
protocol. rCBD cDNAwas excised out of the pUC19 vector
and cloned into a glutathione-S-transferase (GST) fusion
expression vector, pGEX-6P-2 (Amersham Pharmacia Bio-
tech Inc.) to form the construct pGEX-rCBD.
2.2. Expression and purification
Expression and purification were performed as previous-
ly described with modifications [17]. Briefly, pGEX-rCBD
was amplified using E. coli DH5a cells to retain plasmid
integrity. The vector sequence was confirmed through
Sanger dideoxy method (DNA Sequencing Facility, The
Fig. 2. Thermal denaturation of rCBD. The CD spectrum of thermal
denaturation of rCBD (1 mg/ml) at 222 nM shows a sigmoidal curve,
typical of a folded protein.
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dren). The construct was then isolated by Miniprep (Qiagen)
from DH5a cells and transformed into E. coli strain
BL21(DE3) cells for increased expression. Cells were
grown in normal LB media and induced at mid-log phase
for 3.5 h with 0.1 mM isopropyl-1-thio-h-D-galactopyrano-
side (IPTG). Cells were collected, centrifuged for 15 min at
5000 rpm (Beckman Jm-10) and submitted to one to two
freeze thaw cycles as necessary in lysis buffer (25 mM
Tris–HCl, pH 8.0, 130 mM NaCl, 1% Triton X-100, 1 mM
ethylene diamine tetra-acetic acid (EDTA), 10% glycerol, 1
mM phenylmethylsulfonyl fluoride (PMSF), and 0.15 mg/
ml lysozyme). The cells were ultracentrifuged (Beckman L-
90K) at 118,000 g for 45 min. The supernatant liquid was
applied to a GST-affinity column (Amersham Pharmacia),
the pellet was homogenized in solubilization buffer (25 mM
Tris–HCl, pH 8.0, 6 M urea, 130 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol (DTT)), and reultracentrifuged as be-
fore. Solubilization was repeated as necessary. The solubi-
lization supernatant from all centrifugations was dialysed
extensively against 25 mM Tris–HCl, pH 8.0, 10% glycer-
ol, 1 mM EDTA, 1 mM DTT, 1% Triton X-100 (BioRad)
and then applied to a GST-affinity column. The GST-fusion
protein was eluted using buffer containing 25 mM Tris–HCl
pH 8.0, 6 M urea, 80 mM NaCl, 1 mM EDTA, 1 mM DTT.
The quality of fractions was confirmed by SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE). Further purifica-
tions were performed on Sepharose Fast-Q anion exchange
column and eluted using the same buffer but with a NaCl
gradient from 80 to 200 mM. Purified fusion protein was
then dialysed into refolding buffer (elution buffer without
urea) and cleaved using 0.3 units/ml PreScissionk protease
(Amersham Pharmacia Biotech). rCBD was purified from
uncleaved fusion protein and GST by GST affinity column.
Protein quantitation was performed by BCA assay (Pierce).
Protein was stripped of metal when necessary using a
method previously described for the preparation of WCBD
[26,27].Fig. 1. Purification of rCBD. Standard Marker (A). GST-rCBD expression
in BL21(DE3) cells without IPTG (B) and following induction with IPTG
(C). Initial purification by GST affinity chromatography (D) and then by ion
exchange chromatography (E). Purified GST-rCBD was cleaved with
PreScission protease (P). rCBD was purified from GST and GST-rCBD on a
GST affinity column (G).
Fig. 3. Competition of rCBD with 65Zn(II) and transition metals. rCBD (10
Ag/lane) was electrophoresed on 10% SDS-PAGE and transferred to
nitrocellulose. Nitrocellulose strips of rCBD were incubated with 65Zn(II)
and one of a variety of transition metals as described in Section 2. Zn
intensity refers to the digital quantitation of autoradiograph bands and
should not be considered equivalent to binding affinity. Autoradiographs
were overexposed until binding patterns appeared; comparisons of various
metal binding should be made relative to other metals (not to the baseline)
and only qualitatively. Digital quantitation of autoradiographs revealed the
relation in (A) between 65Zn(II) and various metals and (B) in more detail
between 65Zn(II) and Cu(I).
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In order to confirm proper folding after various steps of
purification, samples were examined by thermal denatur-
ation analysis using CD spectroscopic analysis carried out at
222 nm from 25 to 95 jC in 25 mM Tris–Acetate pH 8.0.
All spectra were corrected against buffer and noise reduced.
Spectra were collected and analyzed using an AVIV 62A DS
spectrometer with a 0.1-cm rectangular CD cell. Data points
were collected every 2 jC with intermediary equilibration
times of 1 min.
2.4. 65Zn(II)-competition blotting
Purified rCBD was electrophoresed on a 10% SDS-
PAGE gel, transferred to nitrocellulose membrane (BioRad)
in 10 mM 3-[cyclohexylamino]-1-propanesulfonic acid
(CAPS) (Sigma), pH 11.0 at 300 mA for 1 h 45 min. The
membrane was then cut into strips and soaked in a reducing
binding buffer (100 mM Tris–Cl, pH 7.2, 50 mM NaCl, 1
mM DTT) for 2 h. Individual strips were placed in
incubation tray wells, briefly washed in binding buffer
without DTT. Strips were incubated with 65Zn(II) to a final
concentration of f 4.2 AM in 3 ml of binding buffer
without DTT with various concentrations of competitor
metal for 30 min. When copper was the competitor, DTT
was included to reduce Cu(II) to Cu(I). Strips were washed
twice for 15 min in the same buffer and then exposed to
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rCBD outlining the region containing the CXXC motif. Identical or highly simi
identical; (:) strongly similar; and (.) weakly similar. (C) Structural alignment of t
copper-binding motif, all six have the same tertiary structure, typical of HMA doKodak Biomax MR film for 16–24 h at  70 jC. Auto-
radiographs of nitrocellulose blots were over-exposed to
reveal the lower limit of binding and binding trends.
Therefore, competition results are reported according to
Zn(II) intensity, and due to the design of the experiment,
are only interpreted qualitatively.
2.5. Structural analysis by CD spectroscopy
Separate aliquots of apo-rCBD (29.4 AM) were com-
bined with various concentrations of copper (0–300 AM) in
the form of CuSO4 with 1 mM DTT. The solutions were
equilibrated for 30 min, by which time it was assumed that
all metals were reduced and bound to available sites. Excess
metal and DTTwere dialysed out in argon-purged buffer (50
mM Tris–Acetate pH 8.0). DTT was included to reduce
protein and Cu(II) to Cu(I) but necessarily dialysed out
because of interference experienced in the near-UV range.
Buffer was purged with argon to maintain reduced condi-
tions. CD spectra of Cu(I) samples were collected and
analyzed using a Jasco J-720 spectropolarimeter. Far-UV
CD spectroscopic analyses were employed to qualitatively
monitor the change in structure as increasing amounts of
metal are bound. The effect of metal binding on tertiary
structure was observed by near-UV spectroscopic analyses
that measure the specific aromatic residues and disulfide
content of the protein, factors which are likely to be
dependent on the intrinsic properties of rCBD. Secondaryt it contains the classic HMA fold. (B) Primary sequence alignment of the
lar residues are in bold letters. The degree of similarity is denoted by (*)
he six domains in rCBD reveals that although only five contain the CXXC
mains.
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0.1-cm path length cylindrical CD cell. Tertiary structure
(near-UV, 400–250 nm) changes were recorded using a 2-
cm path length cylindrical CD cell.
2.6. Homology modelling of the N-terminal domains
The rCBD was subjected to homology modelling based
on the solved structures of other HMA domains. SWISS-
Model was used to model the HMA domains of the rCBD
and SWISS-PDB-viewer was used to generate a pictorial
representation of the domains [28–30].Fig. 5. (A) Far-UV spectra of copper-reconstituted rCBD showing the
change in secondary structure in relation to apo with increasing amounts of
copper bound. No significant change in secondary structure is observed
beyond 2–3 molar ratio of copper bound to rCBD. (B) Near-UV spectra of
copper-reconstituted rCBD showing a dramatic change in the directions of
the spectra, when the copper increased from 2 mol of copper bound to 3
mol of copper bound to rCBD.3. Results
3.1. Cloning, expression and purification
We have cloned the DNA segment coding for the rat
N-terminal copper-binding region into a GST pGEX-6P-2
vector. Subsequent expression of this plasmid and cleav-
age of the fusion protein with PreScissionk protease
resulted in free rCBD. rCBD was purified from uncleaved
fusion protein and GST protein by GST affinity and anion
exchange columns. A typical purification process is shown
in Fig. 1. The purity of the final product, rCBD protein,
was determined to be f 95% pure by 10% SDS-PAGE.
Because at least part of the purification process involved
denaturation by urea, thermal denaturation was employed
to confirm refolding. Thermal denaturation curve of puri-
fied rCBD observed at 222 nm displays a sigmoid shape
(Fig. 2), indicating that the protein has a compact con-
formation typical of folded structures and native proteins.
This was also supported by earlier investigation of
WCBD showing that the CD profile of protein that had
undergone denaturation and refolding during purification
was similar to protein purified under non-denaturing
conditions [26].
3.2. 65Zn(II)-competition blotting
The binding of certain transition metals was investigated
by the use of a 65Zn(II)-blot assay; a summary of results is
given in Fig. 3. Zinc(II) has previously been shown to bind
to the metal-binding domain of ATP7B [17]. Fig. 3A shows
that various transition metals were able to successfully bind
to the protein and displace 65Zn(II) while others did not.
rCBD shows an affinity for Cu(I)>Ag(I)>Hg(II)>Au(III)>C-
d(II)>Cr(III)>Fe(III). As the concentration of Cu(I), Ag(I),
Hg(II) and Au(III) was increased, 65Zn(II) was displaced in
a linear fashion (Fig. 3A). Co(II), Mg(II), and Ca(II) did not
appear to be able to compete with 65Zn(II) at all, while
Cd(II), Cr(III) and Fe(III) competed to a lesser extent. A
more detailed analysis of copper as the competitor to
65Zn(II) reveals a sigmoidal pattern, characteristic of a
cooperative interaction of metal with the protein (Fig. 3B).3.3. Homology modelling of rCBD
The common belief has been that atp7b contains five
HMA domains while ATP7B contains six; this has been
considered to be the key difference between these two
copper transporting P-type ATPases. Our homology mod-
elling of the rCBD has revealed an additional domain,
which had not been immediately obvious from the primary
sequence alone (Fig. 4A). Due to the absence of the
CXXC sequence motif from this region, which corre-
sponds to the fourth domain in WCBD, rCBD was
considered to be missing this domain [10], and remained
undetected until now. The sequence alignment of the
domains within rCBD reveals that although only five
contain the CXXC Cu(I)-binding sites (Fig. 4B), the six
domains not only share significant sequence similarity and
conservation of hydrophobic residues, but more impor-
tantly they all possess the fold typical of HMA domains
(Fig. 4C).
ysica Acta 1688 (2004) 78–85
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Molar ellipticity at 220 nm (Fig. 5A) shows that the
secondary structure of rCBD increases in direct relation to
the addition of Cu(I). Above a ratio of 2–3 mol of Cu(I) per
mole of rCBD, no significant changes in the secondary
structure are observed. Near-UV CD was employed to
further characterize the metal binding characteristics of
Cu(I) reconstituted rCBD. At 260 nm, the molar ellipticity
increases proportionally to an incremental addition of Cu(I)
until 2 mol of Cu(I) is added. Upon the addition of 2 and 3
mol of copper per mole of protein, there is a radical change
in the direction of the spectra indicating a critical change in
the environment surrounding aromatic residues (Fig. 5B).
Extrapolation from this wavelength clearly demonstrates
that major tertiary structural changes are occurring between
2 and 3 mol of Cu(I) per mole of rCBD (Fig. 6A). Although
the aromatic residues clearly reflect the structural changes of
rCBD, disulfide spectra may more clearly elucidate events
at the individual binding sites. Molar ellipticities at 240–
350 nm are responsible for a broad disulfide signal; how-
ever, because of interferences by tryptophan and tyrosine,
disulfide signals are only measurable when they make a
significant contribution to the signal and when measured at
above 320 nm [31]. An analysis of CD spectra at an
M.J. Tsay et al. / Biochimica etFig. 6. Near-UV CD spectra extrapolations. (A) CD extrapolation as a
function of number of moles of Cu(I) bound rCBD at (x) 260, (n) 290, and
(E) 330 nm. (B) CD extrapolation of different ratios of Cu(I) bound to
rCBD at (E) 330 nm.absorbance of 330 nm shows that the molar ellipticity/
residue decreases in direct relation to the addition of Cu(I)
to apo rCBD but does not change beyond 5 mol Cu(I) per
mole of protein (Fig. 6B).4. Discussion
This report describes the structural and metal-binding
characteristics of the rCBD, in light of the discovery of the
presence of the fourth HMA-like domain, which was
previously thought to be missing in rCBD. The ability of
different transition metals to compete with 65Zn(II) and to
bind to rCBD confirms earlier reports of multi-metal bind-
ing to copper-transporting ATPases [17]. Indeed, our experi-
ments show that metals other than copper are binding to
rCBD; this is not surprising considering that the CXXC site
in the metal-binding domains is ubiquitously found across
species in different kinds of metal transporting proteins such
as in the E. coli Zn(II) transporter, ZntA [32] or the
mercury-transporting protein MerP [33]. rCBD’s diverse
metal affinity implies that in vivo atp7b is able to discrim-
inate among these metals by a mechanism other than
binding ability alone. Copper(I) and Ag(I) (data not shown)
are the only metals among those capable of binding to rCBD
that displayed cooperativity upon binding. Considering that
atp7b is a known copper-transporting protein, and that Cu(I)
[12,13,24,34–36] and Ag(I) [34] are the only two metals
capable of inducing the kind of metal dependent trafficking
that has become the hallmark of this class of proteins, it is
reasonable that the interaction of Cu(I) and Ag(I) with rCBD
would induce a response distinct from those of other
transition metals. Previous studies have shown that the most
likely configuration for Cu(I) bound to HMA domains is
that of a bent 2-coordinate linear system [19,22]. It is
interesting to point out that despite rCBD having one less
CXXC copper-binding site than WCBD, they both display a
similar pattern of cooperativity upon Cu(I) binding [17].
This indicates that the tertiary structure of the rCBD may be
an important factor in the cooperative metal binding char-
acter displayed. It appears that the absence of the CXXC site
from the fourth domain does not alter the cooperative
binding of metal to the remaining domains, as long as the
HMA fold is present, and the important tertiary protein–
protein contacts between the HMA domains are maintained.
This raises an interesting question: if a conformational
change is a necessary precursor for the translocation of the
protein from the trans-Golgi network to the plasma mem-
brane [35,37] as already hypothesised [22,26], is this
cooperativity of copper binding related to the copper in-
duced translocation?
CD spectroscopy was used to monitor the conformational
changes in the rCBD upon the binding of Cu(I). The
changes observed in the far-UV CD spectra are indicative
of changes in secondary structure, and the changes observed
in the near-UV spectra are indicative of changes in the
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general. When apo rCBD is slowly titrated with Cu(I),
significant changes occur in the secondary structure and
aromatic regions of the CD spectra, most distinctive is the
transition from the apo to the 1:1 state. In vivo this can
translate to a transition from low Cu(I) to elevated Cu(I)
conditions, inducing a conformational change in the rCBD
and influencing the function of atp7b. These results may
point to the conformational change in the N-terminal region
as a possible trigger of the translocation event to the plasma
membrane; this is also suspected to be the case from the
results of the mutational studies on ATP7B [14] and ATP7A
[12,13].
Current literature tends to support two hypotheses on the
function of the metal-binding region of the copper-trans-
porting ATPases. It is commonly accepted that although not
necessary for copper-transport across the membrane, the
metal-binding region plays a central role in the copper-
dependent trafficking and regulation of copper-transporting
ATPases. In general, Cu(I) is believed to bind to the HMA
domains and then transport across the membrane, likely by a
channel formed by the eight transmembrane helices present
in the ATPases. The metal-binding region may also serve a
second function, that of a metal ‘‘sensor’’ [6,17,18,34]. The
gradual change in secondary structure, as observed by far-
UV CD spectra, supports a model where Cu(I) binds to
sensor HMA domains and induces conformational change.
The results in the near-UV/tertiary structure region sup-
port results from both far-UV experiments and 65Zn(II)
competition assays. The changes in molar ellipticity/residue
in response to the addition of copper to rCBD, at 260, 290
and 330 nm are similar in pattern to those observed for
WCBD [26]. The molar ellipticity/residue at 330 nm
decreases linearly both in the case of rCBD and WCBD
but does not change beyond 5 and 6 mol of copper for each,
respectively. Considering that only five of the six domains
of the rCBD contain the CXXC copper-binding site, and are
likely to have similar metal-binding affinities due to se-
quence and structural similarities, this result is in agreement
with the results obtained from structural homology model-
ling and provides further evidence that copper binds at the
CXXC motif and that there is only one copper binding per
CXXC containing HMA domain. Also, these results suggest
that the ratio of fully saturated rCBD is 5 mol of copper
bound per mole of rCBD.
It should be noted that although rCBD contains five
metal-binding motifs and the WCBD contains six, the
breakpoint for structural change in rCBD (Fig. 3) is similar
to that found in WCBD [26] despite the missing CXXC
Cu(I)-binding site. This observation is supported by the
homology modelling of the rCBD, which indicates the
presence of six domains having the HMA domain fold
(Fig. 4). Since rD4 lacks the CXXC metal-binding motif
(Fig. 4A), the fourth CXXC does not appear to be crucial for
cooperative binding copper binding to rCBD or structural/
conformational changes as long as the overall HMA domainfold is present. In addition, the lack of this site does not
appear to affect the multi-metal binding affinity of rCBD
observed in competition studies (Fig. 3), similar to studies
with WCBD [17]. Another possibility may be that the rD4
may not serve a vital function in copper transport or that the
loss of the CXXC sequence motif is an evolutionary
adaptation that enables copper to bind or transport more
efficiently. The similarity in the pattern of binding as
observed in the WCBD [26] and in rCBD tends to imply
that the structural response to metal binding will also be
similar. The fact that both the WCBD and the rCBD have an
equal number of structurally homologous HMA domains is
in support of this argument. However, since there are no
studies confirming the order in which copper binds to
ATP7B or related proteins, it is difficult to make definitive
conclusions about the specific role that HMA domain 4 in
ATP7B and atp7b may play.
It has been known for some time that not all of the
copper-binding domains of the N-terminal region are re-
quired for the copper-transport function of the ATPase
[13,14], and that the conformational changes in the N-
terminal copper-binding region in response to metal binding
may have functional consequences for the ATPase
[12,13,15]. Our studies propose that the metal-dependent
conformational changes observed in the N-terminal region
of these ATPases may not require the presence of a CXXC
motif on every domain, as long as the domain has the proper
shape, which is an HMA-domain-like fold, and as long as
some of them contain the CXXC metal binding sites. The
breakpoint in the binding trend, observed at around 2–3 mol
of copper in the near-UV CD spectra, may well correspond
to the breakpoint determined by 65Zn(II)-blots. This sug-
gests that at a certain point during the cooperative binding of
Cu(I), protein–protein interactions among the HMA
domains begin to dominate the conformational changes in
rCBD, while metal binding to the HMA domains makes a
smaller contribution.Acknowledgements
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